Vertex Suffers Setback In Its Search For Post-CF Blockbusters
Analysts Doubt Pipeline Potential
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
You may also be interested in...
The Phase I trial of IONIS-ENAC-2.5Rx for cystic fibrosis represents the first time an antisense medicine delivered directly to the lung has shown a significant reduction in ENaC messenger RNA levels.
Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.